EDAP TMS (FOCL)
NASDAQ:FOCL
Want to see FOCL full AI Analyst Report?
Top Page
EDAP TMS
(NASDAQ:FOCL)
Select Model
Select Model
Rating:55Neutral
Price Target:
$5.00
▲(43.27% Upside)
Action:Reiterated
Date:06/27/26
The score is held back primarily by weak financial performance—ongoing operating losses and sizable negative operating/free cash flow. Offsetting factors include strong earnings-call momentum and reiterated 2026 growth guidance, plus constructive technical trend signals, though indicators suggest the stock is near-term overbought. Valuation remains middling due to negative earnings and no dividend yield support.
Positive Factors
HIFU Revenue Growth
Sustained double-digit capital sales and 78% YoY HIFU revenue growth reflect accelerating commercial adoption and expanding installed base. This durable demand increases recurring consumable/service revenue potential and creates leverage in per-system economics as placements scale over multiple quarters.
Negative Factors
Negative Cash Flow
Persistent operating and free cash flow deficits signal structural cash burn that can force frequent external financing. Over the medium term this raises refinancing and dilution risk, constraining the company’s ability to fund scaling, R&D, and international commercialization without recurring capital raises.
Read all positive and negative factors
Positive Factors
Negative Factors
HIFU Revenue Growth
Sustained double-digit capital sales and 78% YoY HIFU revenue growth reflect accelerating commercial adoption and expanding installed base. This durable demand increases recurring consumable/service revenue potential and creates leverage in per-system economics as placements scale over multiple quarters.
Read all positive factors
EDAP TMS (FOCL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$191.16M
Dividend YieldN/A
Average Volume (3M)36.57K
Price to Earnings (P/E)―
Beta (1Y)0.97
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees310
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.49
Shares Outstanding37,481,987
10 Day Avg. Volume28,395
30 Day Avg. Volume36,573
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)6.35
Price to Sales (P/S)1.74
P/FCF Ratio-5.76
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue4.94
Enterprise Value/Gross Profit11.24
Enterprise Value/Ebitda-15.43
Forecast
1Y Price Target
$10.00Price Target Upside186.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.88
Revenue Forecast (FY)$65.20M
EDAP TMS Business Overview & Revenue Model
Company Description
EDAP TMS S.A. operates as a holding company, with its subsidiary primarily focused on the innovation, manufacturing, and distribution of advanced, minimally invasive medical devices engineered to address urological conditions. The company's activi...
How the Company Makes Money
EDAP makes money by selling capital equipment (medical devices) and generating recurring revenue tied to the installed base. A primary revenue stream is the sale of its HIFU systems (e.g., urology therapeutic ultrasound platforms) to healthcare pr...
EDAP TMS Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
55
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 39.74M | 70.75M | 69.35M | 65.32M | 57.92M | 52.08M |
| Gross Profit | 17.48M | 30.09M | 28.73M | 26.39M | 25.43M | 21.77M |
| EBITDA | -12.73M | -25.05M | -17.70M | -20.31M | -915.40K | 2.66M |
| Net Income | -18.57M | -29.34M | -20.57M | -22.90M | -3.08M | 827.39K |
Balance Sheet | ||||||
| Total Assets | 72.06M | 79.00M | 89.12M | 101.13M | 107.92M | 87.82M |
| Cash, Cash Equivalents and Short-Term Investments | 15.01M | 20.45M | 30.90M | 48.02M | 67.38M | 53.66M |
| Total Debt | 27.79M | 27.68M | 14.41M | 9.37M | 10.02M | 11.38M |
| Total Liabilities | 61.96M | 59.58M | 46.77M | 38.25M | 31.47M | 30.90M |
| Stockholders Equity | 10.10M | 19.41M | 42.35M | 62.88M | 76.45M | 56.92M |
Cash Flow | ||||||
| Free Cash Flow | -7.82M | -21.40M | -16.12M | -17.14M | -3.82M | 4.79M |
| Operating Cash Flow | -5.37M | -16.46M | -14.69M | -15.87M | -3.18M | 5.26M |
| Investing Cash Flow | -2.45M | -5.73M | -4.46M | -4.70M | -2.50M | -1.94M |
| Financing Cash Flow | 10.12M | 8.64M | 5.01M | -984.90K | 22.85M | 23.95M |
EDAP TMS Technical Analysis
Positive
3.49
Price Trends
4.18
Positive
4.12
Positive
3.42
Positive
Market Momentum
0.23
Negative
71.45
Negative
72.32
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FOCL, the sentiment is Positive. The current price of 3.49 is below the 20-day moving average (MA) of 4.75, below the 50-day MA of 4.18, and above the 200-day MA of 3.42, indicating a bullish trend. The MACD of 0.23 indicates Negative momentum. The RSI at 71.45 is Negative, neither overbought nor oversold. The STOCH value of 72.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FOCL.
EDAP TMS Risk Analysis
EDAP TMS disclosed 42 risk factors in its most recent earnings report. EDAP TMS reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
EDAP TMS Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $188.43M | -20.22 | -90.62% | ― | 18.22% | 59.78% | |
56 Neutral | $58.92M | 31.83 | 3.68% | ― | -0.32% | ― | |
55 Neutral | $191.16M | -6.22 | -148.90% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $16.73M | -0.85 | -211.73% | ― | 8.92% | 17.50% | |
45 Neutral | $33.72M | -1.27 | -81.52% | ― | 54.38% | 7.25% |
* Healthcare Sector Average
FOCL
EDAP TMS
5.10
3.45
209.09%
APYX
Apyx Medical
4.50
2.25
100.00%
NSPR
InspireMD
0.72
-1.55
-68.28%
XTNT
Xtant Medical Holdings
0.42
-0.32
-43.17%
ICCM
Icecure Medical
5.96
-23.34
-79.66%
EDAP TMS Corporate Events
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and FinancingShareholder Meetings
EDAP TMS Shareholders Approve Governance and Capital Measures
Positive
Jun 26, 2026
At its Annual General Meeting held on June 26, 2026, EDAP TMS shareholders approved a broad slate of governance and capital-related resolutions, including amendments to key bylaw articles on share capital, the Board of Directors and shareholders&#...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.